The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).
Marcel Devetten, MD
Advertisement
Articles by Marcel Devetten, MD
Advertisement
Latest Updated Articles
- Refractory CML: Not All Forms of Resistance Are Equal
April 15th 2008
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO Releases New Patient-Clinician Communication Guidelines
2
What is The State of Radiation Oncology in Head and Neck Cancers?
3
Combining a PCNA Inhibitor with KRAS-Targeting Agents in PDAC
4
Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial
5